SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG

SHR-A2102 ; Adebrelimab injection

SHR-A2102 is administered intravenously, Adebrelimab is administered intravenously

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV